DrugPatentWatch Database Preview
Deutetrabenazine - Generic Drug Details
What are the generic sources for deutetrabenazine and what is the scope of freedom to operate?
Deutetrabenazine
is the generic ingredient in one branded drug marketed by Teva Branded Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Deutetrabenazine has forty-seven patent family members in twenty countries.
Summary for deutetrabenazine
| International Patents: | 47 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 15 |
| Clinical Trials: | 12 |
| Patent Applications: | 9 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | deutetrabenazine at DailyMed |
Recent Clinical Trials for deutetrabenazine
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pennsylvania | Phase 1/Phase 2 |
| Teva Branded Pharmaceutical Products, R&D Inc. | Phase 1/Phase 2 |
| Nuvelution TS Pharma, Inc. | Phase 3 |
Synonyms for deutetrabenazine
| (+)-Tetrabenazine D6 |
| (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one |
| (3RS,11Brs)-9,10-di((2H3)methoxy)-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizin-2-one |
| [2H6]-(+)-Tetrabenazine|||[2H6]-(+)- 9,10-Dimethoxy-1,3R,4,6,7,11bR-hexahydro-3-isobutyl-2H-benzo[a]quinolizin-2-one |
| 1392826-25-3 |
| 1977511-05-9 |
| 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-, (3R,11bR)-rel- |
| Austedo |
| Austedo (TN) |
| CHEMBL3137326 |
| D10701 |
| DB12161 |
| Deutetrabenazine (USAN/INN) |
| Deutetrabenazine [USAN:INN] |
| Dutetrabenazine |
| GTPL8707 |
| HY-B0590S |
| Q27077026 |
| Ro 1-9569 D6 |
| SCHEMBL13321841 |
| SCHEMBL16227993 |
| SCHEMBL16228022 |
| SD 809 |
| SD-809 |
| SD809 |
| Tetrabenazine D6 |
| Tetrabenazine-d6 |
| UNII-P341G6W9NB component MKJIEFSOBYUXJB-VFJJUKLQSA-N |
| UNII-P341G6W9NB component MKJIEFSOBYUXJB-WEZHFFAMSA-N |
US Patents and Regulatory Information for deutetrabenazine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-002 | Apr 3, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for deutetrabenazine
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2326643 | Start Trial |
| Japan | 5970037 | Start Trial |
| European Patent Office | 3061760 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
